Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis

Julia C Cutts; Rosanna Powell; Paul A Agius; James G Beeson; Julie A Simpson; Freya J I Fowkes

doi:10.1186/s12916-014-0150-1

Table 1 Characteristics of studies included in the systematic review by country

From: Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis

Author, year [reference]	Region	Age range, years	Antibody response (type)	Study design (n)^a	*Plasmodium vivax*outcome^b
Brazil
Fernandez-Becerra, 2010 [22]^c	Rio Machado	DNS	PvMSP-1_NT, PvMSP-1₁₉ (IgG)	CS (87)	Pv infection (LM or PCR), symptomatic Pv
Kano, 2012 [23]	Presidente Figueiredo, Amazonas	9 to 44	PvDBPII-IV, PvMSP-1₁₉ (IgG)	CS (432)	Pv infection (LM or PCR), symptomatic Pv
Lima-Junior, 2008 [24]^d	Rondonia	10 to 85	PvMSP-9_RIRII, PvMSP-9_RII, PvMSP-9_NT (IgG)	CS (282)	Pv infection
Lima-Junior, 2011 [25]	Rondonia	10 to 81	PvMSP-3α_FL, PvMSP-3α_NT, PvMSP-3α_RI, PvMSP-3α_RII, PvMSP-3α_CT (IgG)	CS (282)	Pv infection
Lima-Junior, 2012 [26]	Rondonia	11 to 89	PvMSP-1₁₉ (IgG)	CS (277)	Pv infection
Nogueira, 2006 [27]	Portuchuelo, Rondonia	DNS	PvMSP-1_NT, PvMSP-1₁₉ (IgG)	Cohort (173)	Pv infection
Oliveira-Ferreira, 2004 [28]	Candeias do Jamari, Rondonia	12 to 74	PvCSP (VK210, VK247, P. vivax-like) (IgG)	CS (61)	Pv infection
Souza-Silva, 2010 [29]	Acre	5 to 90	PvDBPII-IV (IgG)	Cohort (CS)^e (366)	Pv infection, Pv infection (LM or PCR)
Tran, 2005 [30]^f	Colina and Ribeirinha, Rondonia	11 to 75	PvRBP1 (IgG)	CS (87)	Pv infection
Versiani, 2013 [31]	Rio Pardo	DNS	PvMSP-1_NT (IgG, IgG1, IgG2, IgG3, IgG4)	Cohort (CS)^e (308)	Pv infection, symptomatic Pv
Indonesia
Ak, 1998 [32]	Robek	0 to 73	PvMSP-1₁₉ (IgG + IgM)	CS (169)	Pv infection
Woodberry, 2008 [33]	Timika, Papua	3 to 60	PvMSP-5 (IgG, IgM, IgG1, IgG2, IgG3, IgG4)	CC (340)	Symptomatic Pv
Papua New Guinea
Cole-Tobian, 2009 [34]	Madang	5 to 14	PvDBPII (AH, O, P, Sal 1), PvMSP-1₁₉ (IgG)	Cohort^g (206)	Pv infection, Pv infection (LDR-FMA), Pv infection >150 parasites/μl
Fernandez-Becerra, 2010 [22]	Madang	0.25 to 3	PvMSP-1_NT, PvMSP-1₁₉ (IgG)	CS (100)	Pv infection (LM or PCR), symptomatic Pv
King, 2008 [35]	Madang	5 to 14	PvDBPII binding inhibitory antibodies	Cohort (206)^h	Pv infection
Stanisic, 2013 [36]	East Sepik	0.9 to 3.1	PvMSP-3α_NT, PvMSP-3α_RI, PvMSP-3α_RII, PvMSP-3α_CT, PvMSP-9_NT, PvMSP-9_RIRII (IgG)	Cohort (CS)^e (183)	Pv infection (LDR-FMA), symptomatic Pv
Thailand
Fowkes, 2012 [37]	Mae Sot, Tak	15 to 42ⁱ	PvAMA1-ecto (IgG)	Nested CC (467)	Pv infection
Wongsrichanalai, 1991 [38]	Chanthaburi	DNS	PvCSP (VK210) (IgG)	CC (126)	Pv infection
Turkey
Yildiz Zeyrek, 2011 [39]	Sanliurfa	0 to 77	PvMSP-1₁₉, PvAMA1-ecto, PvSERA4, PvCSP (VK210 and VK247 chimera) (IgG, IgM, IgG1, IgG2, IgG3, IgG4)	CS (195)	Pv infection

CC, case-control; CS, cross-sectional; DNS, did not state; LDR-FMA, ligase detection reaction-fluorescent microsphere assay; LM, light microscopy; PV, Plasmodium vivax.
^aSample size refers to number of participants for whom serology was determined.
^b P. vivax infection was determined by light microscopy unless otherwise stated.
^cFernandez-Becerra, 2010 [22] reported studies performed in two countries and features twice in Table 1.
^dThe studies described by Lima-Junior in 2008 and 2012 [24],[26] were conducted in the same area, but the participants were different.
^eCohort study with cross-sectional data also included.
^fTran, 2005 [30] included data from two different study sites in Brazil.
^gTreatment to re-infection study.
^hKing, 2008 [35] reported estimates from the same treatment to re-infection study as that described by Cole-Tobian, 2009 [34].
ⁱThis study comprised pregnant women.

Back to article page